candesartan cilexetil + placebo
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cluster Headache
Conditions
Cluster Headache
Trial Timeline
Mar 1, 2005 → Dec 1, 2009
NCT ID
NCT00184587About candesartan cilexetil + placebo
candesartan cilexetil + placebo is a phase 2 stage product being developed by AstraZeneca for Cluster Headache. The current trial status is completed. This product is registered under clinical trial identifier NCT00184587. Target conditions include Cluster Headache.
What happened to similar drugs?
1 of 7 similar drugs in Cluster Headache were approved
Approved (1) Terminated (0) Active (6)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00120003 | Phase 3 | Completed |
| NCT00184587 | Phase 2 | Completed |
Competing Products
8 competing products in Cluster Headache
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Galcanezumab 300 mg + Placebo | Eli Lilly | Phase 3 | 40 |
| Galcanezumab | Eli Lilly | Phase 3 | 40 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 40 |
| SOM230 + Placebo | Novartis | Phase 2 | 27 |
| Bosutinib + Imatinib | Pfizer | Phase 3 | 40 |
| Eptinezumab + Placebo | Lundbeck | Phase 3 | 37 |
| Eptinezumab | Lundbeck | Phase 3 | 37 |
| Methylprednisolone | Brain Biotech | Approved | 33 |